Clinical Trials

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT00699751 2026-02-23

ALSYMPCA

921 enrolled 43 charts

Hormone Refractory Prostate Cancer

NCT04521361 2025-09-19

A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

46 enrolled

Bone Metastatic Castration-resistant Prostate Cancer

NCT02043678 2025-02-19

ERA 223

806 enrolled 32 charts

Prostatic Neoplasms

NCT03996473 2024-10-10

Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

Phase 1 Terminated

8 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

283 enrolled 22 charts

Breast

Breast Neoplasms

NCT00337155 2023-11-02

BAY88-8223, Dose Finding Study in Patients With HRPC

122 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT00667199 2023-04-19

BAY88-8223, Does Response Study in HRPC Patients

100 enrolled

Hormone Refractory Prostate Cancer

NCT02258464 2020-08-10

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Phase 2 Terminated

99 enrolled 18 charts

Breast

Breast Neoplasms

NCT02928029 2020-02-26

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

Phase 1/2 Terminated

7 enrolled 9 charts

Plasma cell

Multiple Myeloma

NCT02814669 2019-09-24

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

45 enrolled

Castrate-Resistant Prostate Cancer

NCT02034552 2019-07-23

A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)

68 enrolled 17 charts

Prostatic Neoplasms

NCT02023697 2019-07-12

Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone

391 enrolled 53 charts

Prostatic Neoplasms

NCT01810770 2018-09-19

Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis

243 enrolled

Prostatic Neoplasms

NCT01929655 2018-04-24

Japanese BAY88-8223 Monotherapy Phase II Study

49 enrolled

Prostatic Neoplasms

NCT01934790 2018-03-26

Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases

Phase 1/2 Completed

45 enrolled 23 charts

Prostatic Neoplasms

NCT01798108 2017-05-19

Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases

31 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT01618370 2017-03-31

Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

705 enrolled

Prostatic Neoplasms

NCT01106352 2017-01-04

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Phase 1/2 Completed

70 enrolled 26 charts

Bone Metastases

NCT02442063 2016-11-30

Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions

15 enrolled

Bone Diseases, Neoplasms

NCT01565746 2016-10-17

Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients

19 enrolled

Prostatic Neoplasms

NCT02605356 2016-10-07

Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma

Phase 1/2 Withdrawn

Plasma cell

Multiple Myeloma

NCT00667537 2015-12-14

PK in Pts With HRPC & Skeletal Metastes

6 enrolled

Prostatic Neoplasms

NCT00459654 2014-06-25

A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

64 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT00748046 2014-06-25

Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

10 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT01070485 2014-06-25

BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease